Risk of cancers during interrupted antiretroviral therapy in the SMART study

2007136 citationsJournal Article

Authors

Michael J. Silverberg · Kaiser Permanente

Jacqueline Neuhaus · University of Minnesota

Mark Bower · Chelsea and Westminster Hospital

Daniela Gey · University of Copenhagen

Angelos Hatzakis · National and Kapodistrian University of Athens

Keith Henry · AIDS Clinical Trials Group

José A. Hidalgo

Abstract

Non-AIDS-defining malignancies were more common in this cohort than AIDS-defining malignancies. This analysis provides further evidence against the use of CD4 T-cell-guided ART because of a higher risk of AIDS-defining malignancies in addition to opportunistic infections and deaths.

Topics & Keywords

Viral-associated cancers and disorders Lymphoma Diagnosis and Treatment HIV/AIDS drug development and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 21, Issue 14, pp. 1957-1963

DOI: 10.1097/qad.0b013e3282ed6338

Field-Weighted Citation Impact: 7.66